It has been suggested that the pattern of chemoresistance found in many solid tumors may be due to their failure to efficiently activate programmed cell death (PCD) processes upon exposure to chemotherapeutic agents. Nevertheless, despite the fact that it is often difficult to activate PCD in these tumors, it is still possible to kill them selectively using certain chemotherapeutic drugs, suggesting that either these agents are particularly good at precipitating PCD in such tumors, or that these drugs are able to kill through mechanisms that don't require activation of PCD (i.e., by non-programmed cell death processess). Our studies suggest that both programmed and non-programmed forms of cell death may be important in mediating fluoropyrimidine cytotocicity. In this application we propose a model to define the relative roles of programmed- and non-programmed death processes in cells exposed to these drugs. Our objective is to evaluate that model by testing predictions about the consequences of modulating proteins involved in the formation of DNA lesions following thymidylate synthase inhibition (uracil-DNA-glycosylase), progression of cells though the cell cycle (p21/WAF1/Cip1) or the activation of programmed cell death processes (Bcl-X) in the HT29 human collorectal carinoma cell line.
Our specific aims are given below, in the form of hypotheses to be tested. H1: Inhibition of uracil excision-repair activity in FdUrd-treated HT29 cells will increase uracil incorporation into DNA, while decreasing overall cytotoxicity and DNA single- and double-strand break formation H2: Temporary inhibition of S-phase progression in FdUrd-treated HT20 cells (by conditional enforcement of a G1/S checkpoint using p21/WAF1/Cip1) will not affect formation of DNA single stand breaks in parental DNA, but will reduce or eliminate DNA double-strand break formation and cytoxicity. H3: Temporary expression of Bcl-XS (which antagonizes the anti-PCD effect of Bcl-XL) will increase FdUrd-induced cytotoxicity in HT29 cells and will change the pattern of FdUrd-induced DNA fragmentation to one that is characteristic of PCD, without affecting uracil incorporation into DNA or DNA single-strand break formation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA056663-06
Application #
2856319
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Program Officer
Forry-Schaudies, Suzanne L
Project Start
1993-01-01
Project End
2000-12-31
Budget Start
1999-01-01
Budget End
2000-12-31
Support Year
6
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Pharmacology
Type
Schools of Medicine
DUNS #
791277940
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Fridman, J S; Parsels, J; Rehemtulla, A et al. (2001) Cytochrome c depletion upon expression of Bcl-XS. J Biol Chem 276:4205-10
Fridman, J S; Benedict, M A; Maybaum, J (1999) bcl-X(S)-induced cell death in 3T3 cells does not require or induce caspase activation. Cancer Res 59:5999-6004
Rehemtulla, A; Hamilton, A C; Taneja, N et al. (1999) A caspase-resistant form of Bcl-X(L), but not wild type Bcl-X(L), promotes clonogenic survival after ionizing radiation. Neoplasia 1:63-70
Lin, H L; Parsels, L A; Maybaum, J et al. (1999) N-Nitrosodimethylamine-mediated cytotoxicity in a cell line expressing P450 2E1: evidence for apoptotic cell death. Toxicol Appl Pharmacol 157:117-24
Parsels, L A; Parsels, J D; Wagner, L M et al. (1998) Mechanism and pharmacological specificity of dUTPase-mediated protection from DNA damage and cytotoxicity in human tumor cells. Cancer Chemother Pharmacol 42:357-62
Fridman, J S; Rehemtulla, A; Hofmann, A et al. (1998) Expression of Bcl-XS alters cytokinetics and decreases clonogenic survival in K12 rat colon carcinoma cells. Oncogene 17:2981-91
Parsels, L A; Zellars, R C; Loney, T L et al. (1997) Prevention of fluorodeoxyuridine-induced cytotoxicity and DNA damage in HT29 colon carcinoma cells by conditional expression of wild-type p53 phenotype. Mol Pharmacol 52:600-5
Merchant, A K; Loney, T L; Maybaum, J (1996) Expression of wild-type p53 stimulates an increase in both Bax and Bcl-xL protein content in HT29 cells. Oncogene 13:2631-7
Lawrence, T S; Davis, M A; Tang, H Y et al. (1996) Fluorodeoxyuridine-mediated cytotoxicity and radiosensitization require S phase progression. Int J Radiat Biol 70:273-80
Tang, H Y; Weber, K L; Lawrence, T S et al. (1996) Dependence of fluorodeoxyuridine-induced cytotoxicity and megabase DNA fragment formation on S phase progression in HT29 cells. Cancer Chemother Pharmacol 37:486-90

Showing the most recent 10 out of 15 publications